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The human T-lymphotropic virus type 1 (HTLV-1) is efficiently transmitted through cellular
contacts. While the molecular mechanisms of viral cell-to-cell propagation have been
extensively studied in vitro, those facilitating the encounter between infected and target cells
remain unknown. In this study, we demonstrate that HTLV-1-infected CD4 T cells secrete a
potent chemoattractant, leukotriene B4 (LTB4). LTB4 secretion is dependent on Tax-induced
transactivation of the pla2g4c gene, which encodes the cytosolic phospholipase A2 gamma.
Inhibition of LTB4 secretion or LTB4 receptor knockdown on target cells reduces T-cell
recruitment, cellular contact formation and virus propagation in vitro. Finally, blocking the
synthesis of LTB4 in a humanized mouse model of HTLV-1 infection significantly reduces
proviral load. This results from a decrease in the number of infected clones while their
expansion is not impaired. This study shows the critical role of LTB4 secretion in HTLV-1
transmission both in vitro and in vivo.
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T
he human T-lymphotropic virus type 1 (HTLV-1) is
estimated to infect 5–20 million people worldwide1.
Among HTLV-1-infected individuals, 90–95% remain
asymptomatic throughout their lives. Nevertheless, HTLV-1 is
the aetiological agent of many severe diseases, ranging from an
aggressive lymphoproliferation, the adult T-cell leukaemia/
lymphoma (ATL), to inflammatory syndromes, such as
myositis, uveitis, infective dermatitis and a neurodegenerative
disease called HTLV-1-associated myelopathy or tropical spastic
paraparesis (HAM/TSP)2. HTLV-1-associated pathologies often
develop in individuals with high proviral load (PVL), that is,
elevated frequency of infected cells, mostly CD4 T cells3,4.
A major feature of HTLV-1 is that infection almost exclusively
occurs through cell-associated virus. First, there is no viraemia
associated with HTLV-1 infection, HTLV-1 genomic RNA is
rarely detected in the plasma of infected individuals5. In addition,
it is estimated that 106 HTLV-1 particles are needed to infect one
primary activated lymphocyte in vitro, underlining the low
infectivity of the viral particles6. In vivo, contamination through
blood transfusion requires the transfer of at least 108 PBMCs7,
hence the probability of HTLV-1 infection on leukoreduction is
virtually null8,9. Dendritic cells seem to be the only cell type
sensitive to infection through free viral particles10, although
infection is still poorly efficient in vitro11.
Several non-exclusive mechanisms of viral transmission during
cell–cell contact have been described: virus can spread through
viral synapses, cellular conduits or transferred embedded in a
viral biofilm12–14. The mechanisms facilitating the encounter
between an infected cell and a target cell remain unclear15.
Previous studies have demonstrated that HTLV-1-infected cells
have an increased migratory capacity, which may facilitate the
encounter with potential target cells16–18. We postulate that target
cells are recruited to the vicinity of HTLV-1-infected cells
through the effect of chemoattractants released by the latter19.
A recent study has reported that the levels of leukotriene B4
(LTB4) are higher in the plasma of HTLV-1-infected individuals
than of uninfected individuals20. LTB4 is a potent
chemoattractant that favours the recruitment of leukocytes to
inflammation sites21–25. LTB4 is a metabolite of arachidonic acid
(AA). It is synthesized by the sequential action of 5-lipoxygenase
(5-LO) and leukotriene A4 hydrolase26. It mediates its effects by
binding to the G-protein-coupled receptor BLT-1 (ref. 27). LTB4
is mostly secreted by neutrophils, mast cells, monocytes and
macrophages28. Under physiological condition, lymphocytes do
not secrete LTB4; the limiting factor for LTB4 secretion in
lymphocytes is the synthesis of AA29–32. AA is released from
membrane lipids by enzymes with a phospholipase A2 (PLA2)
activity33. In the human genome, more than 30 enzymes possess a
PLA2 activity; they are divided into nine separated groups, based
on their structure, subcellular localization and enzymatic
activity34.
In this study, we evaluate the role of LTB4 in HTLV-1
propagation. We demonstrate that HTLV-1-infected CD4 T cells
secrete LTB4. We find that this secretion is the consequence of
the overexpression of the cytosolic PLA2 gamma (cPLA2g)
induced by the viral transactivator Tax. We also show that LTB4
secretion facilitates the recruitment of T cells and virus
transmission in vitro. Finally, we demonstrate that humanized
mice infected with HTLV-1 and treated with a LTB4-inhibitor
display fewer independent HTLV-1-infected cellular clones and
lower HTLV-1 PVLs.
Results
Infected primary CD4 T cells spontaneously secrete LTB4. It
was previously reported that, on ionomycin stimulation, PBMCs
isolated from HTLV-1-infected individuals secrete significantly
more LTB4 than PBMCs from uninfected healthy donors
(HDs)20. Similarly, we observed that, in the absence of external
stimuli, PBMCs from HTLV-1 asymptomatic carriers (HACs) or
HAM/TSP patients spontaneously secrete higher levels of LTB4
than PBMCs from HDs (Fig. 1a).
We wondered if infected CD4 T cells could participate in such
a secretion. Thus, CD4 T cells were isolated, and the LTB4
secretion capacity was assessed. As described before35, CD4 T
cells isolated from HDs do not secrete detectable levels of LTB4
(Fig. 1b). In contrast, significant levels of LTB4 were detected in
the supernatant of CD4 T cells isolated from HACs or HAM/TSP
patients (Fig. 1b). Considering the proportion of CD4 T cells
among PBMCs for the different donors, we estimated that
20–30% of the LTB4 spontaneously released by PBMCs is
produced by CD4 T cells in HACs; in HAM/TSP, secretion by
CD4 T cells accounts for 80% of the LTB4 released by PBMCs.
Furthermore, LTB4 secretion levels positively correlated with the
percentage of CD4 T cells infected with HTLV-1 (Fig. 1c).
These results on primary cells suggest that, in contrast to
normal CD4 T cells, HTLV-1-infected CD4 T cells spontaneously
secrete LTB4.
LTB4 secretion depends on cPLA2c overexpression by Tax.
We set to determine which viral factor is responsible for
HTLV-1-induced LTB4 secretion. To this aim, Jurkat cells were
transduced with lentivectors encoding either Tax (the viral
transactivator), HBZ (the viral regulatory protein encoded by the
antisens transcript) or the reporter protein GFP as a control.
Expression of the different proteins was confirmed by western
blot (Fig. 2a, right panel). LTB4 was not detected in the
supernatant of cells expressing either HBZ or GFP alone. On the
contrary, Tax expression was sufficient to induce LTB4 secretion
in Jurkat cells (Fig. 2a, left panel).
As the limiting factor for LTB4 secretion in lymphocytes is the
PLA2 activity, we sought to identify which PLA2 protein is
overexpressed in Tax-expressing cells. Thus, we tested the
impact of PLA2 inhibitors on LTB4 secretion (Fig. 2b). Treatment
with BEL (bromoenol lactone), an inhibitor of the group 6 PLA2s
(PLA2G6s), did not affect Tax-induced LTB4 secretion.
In contrast, MAFP (methyl arachidonyl fluorophosphonate)
treatment, which inhibits the PLA2 activity of PLA2G4s
and PLA2G6s, efficiently reduced LTB4 secretion by
Tax-transduced Jurkat cells. We concluded that Tax-induced
LTB4 secretion is dependent on PLA2G4s, also called cytoplasmic
PLA2s (cPLA2s).
As the PLA2G4 family is composed of six members36,
transcript levels for the six isoforms were measured by reverse
transcription followed by quantitative PCR (RT–qPCR).
Both on primary CD4 T cells and Jurkat cells, transcripts
were detected only for two genes: pla2g4a and pla2g4c, which
encode the proteins cPLA2a and cPLA2g, respectively. While
pla2g4a mRNA levels were not affected by Tax expression,
pla2g4c levels were increased in Tax-transduced Jurkat cells
(Fig. 2c). Similarly, pla2g4c mRNA levels were significantly
higher in CD4 T cells isolated from HTLV-1-infected donors
(HACs or HAM/TSP patients), than those isolated from HDs
(Fig. 2d).
Although pla2g4c transcript levels were elevated, cPLA2g could
not be detected (by western blot or FACS). To confirm that LTB4
secretion depends on the cPLA2g enzymatic activity, Jurkat
cells were transduced with shRNAs targeting pla2g4c before
transduction with Tax-encoding lentivectors. Knockdown (KD)
efficiency was confirmed by RT–qPCR (Fig. 2e, left panel). We
found that downregulation of pla2g4c prevented Tax-induced
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secretion of LTB4 (Fig. 2e, right panel), confirming the
implication of cPLA2g.
Overall, these findings demonstrate that, on HTLV-1 infection
and Tax expression, cPLA2g is overexpressed, leading to LTB4
secretion.
Tax activates pla2g4c transcription through NF-jB and CREB.
The pla2g4c promoter was cloned into a luciferase reporter
plasmid. Transfection of the reporter plasmid together with a
plasmid encoding Tax confirmed that the viral transactivator


























































































































Figure 2 | HTLV-1-induced LTB4 secretion depends on Tax-induced cPLA2c overexpression. (a) Tax-expressing Jurkat cells secrete significant levels of
LTB4. Jurkat cells were transduced with lentiviral vectors encoding GFP alone or together with the viral regulatory proteins Tax and HBZ. Protein expression
was detected by western blot 48 h post transduction (right panel). Spontaneous LTB4 secretion levels were determined by ELISA. P value o10 3; n¼4;
mean±s.e.m.; ANOVA, Tukey’s post hoc test. (b) Tax-induced LTB4 secretion is dependent on group 4 phospholipases A2 (PLA2G4). Tax-expressing Jurkat
cells were treated with either 1 mM MAFP or 5 mM BEL for 30 min. Spontaneous LTB4 secretion was detected by ELISA. P value¼0.019; n¼4;
mean±s.e.m.; ANOVA, Tukey’s post hoc test. (c) Pla2g4c transcript levels are increased in Tax-expressing Jurkat cells. Expression levels of pla2g4a
(encoding cPLA2a) and pla2g4c (encoding cPLA2g) were determined by RT–qPCR on Jurkat cells transduced with GFP, Tax or HBZ. mRNA levels were
normalized to gapdh expression and gene expression in Jurkat cells. P value¼ 2.10 3; n¼ 3; mean±s.e.m.; ANOVA test, Tukey’s post hoc test. (d) Pla2g4c
mRNA levels are higher on CD4 T cells from HTLV-1-infected individuals when compared to HDs. CD4 T cells from HDs (n¼ 7), HACs (n¼ 5) and HAM/
TSP (n¼ 5) were isolated by negative selection. RT–qPCR for pla2g4a and pla2g4c was performed. Values were normalized to gapdh expression and the
mean value on CD4 T cells from HDs. P value¼0.007; mean±s.e.m.; Mann–Whitney U-test. (e) Pla2g4c KD counters Tax-induced LTB4 secretion. Jurkat
cells were transduced with vectors encoding a shRNA-targeting pla2g4c (or a control sh-ctrl). Cells were then transduced with Tax. KD efficiency was
determined by RT–qPCR (normalized to gapdh expression and pla2g4c in Jurkat cells) (left panel). LTB4 secretion was detected by ELISA. P value¼0.03;
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Figure 1 | Primary CD4 T cells from HTLV-1-infected individuals secrete LTB4. (a) PBMCs from HTLV-1-infected individuals secrete significantly more
LTB4 than PBMCs from HDs. PBMCs were culture for 30 min and spontaneous LTB4 secretion levels were determined by ELISA. Dashed line represents the
detection limit of the ELISA kit. PBMCs were from HDs (n¼ 5), HACs (n¼ 5) or individuals who had developed HAM/TSP (n¼ 5). Bars represent mean. P
value¼0.03; Mann–Whitney U-test (HDs versus HACs and HAM/TSP). (b) CD4 T cells from HTLV-1-infected individuals secrete detectable levels of
LTB4. CD4 T cells were isolated, cultured for 30 min and spontaneous LTB4 secretion was detected by ELISA. Bars represent mean. P valueo0.001;
Mann–Whitney U-test (HDs versus HACs and HAM/TSP). (c) LTB4 spontaneous secretion by CD4 T cells correlates with the percentage of cells infected
with HTLV-1. Pearson’s correlation test: r¼0.87; R2¼0.76; P value o104.
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Tax is known to activate multiple cellular pathways, including
the CREB and NF-kB pathways. To determine which of these
pathways are responsible for Tax induced pla2g4c expression, we
tested the capacity of two Tax mutants (M22 and M47) to
transactivate pla2g4c. These mutants are unable to activate the
NF-kB and the CREB pathways, respectively37. Expression of the
different mutants was confirmed by western blot (Fig. 3a, right
panel). We found that both mutants failed to activate the pla2g4c
promoter (Fig. 3a, left panel), suggesting that both CREB and NF-
kB pathways are required for efficient Tax-induced pla2g4c
transcription.
Previously, a kB site and a CRE site have been described on the
pla2g4c promoter38. By directed mutagenesis of the
corresponding sequences in the reporter plasmid, we observed
that the promoter depleted for the kB site was no longer
responsive to Tax and the one depleted for the CRE site was only
partially inducible by Tax (Fig. 3b). These confirm the
importance of both cellular pathways.
Secreted LTB4 mediates potential target cell recruitment.
To determine whether the LTB4 secreted by HTLV-1-infected
cells favours the recruitment of potential target cells, we employed
HTLV-1-chronically infected C91/PL cells, which secrete LTB4 at
levels comparable to those secreted by primary infected CD4 T
cells (Fig. 4a). LTB4 secretion can be inhibited using MK886,
an inhibitor of the 5-LO cofactor FLAP, or MAFP (Fig. 4a).
The chemotactic potential of the C91/PL supernatant was
analysed in a compartmentalized Transwell device. Jurkat cells
(present in the upper compartment) migrated significantly more
towards the supernatant of C91/PL cells than towards Jurkat cell
supernatant (Fig. 4b). The supernatant of drug-treated C91/PL
cells displayed a reduced chemotactic capacity on Jurkat (Fig. 4b),
highlighting the importance of LTB4 in chemotaxis. Similarly,
chemotaxis towards C91/PL supernatant was observed with
primary CD4 T cells (Fig. 4c), and was partially inhibited on
treatment of C91/PL cells with the different inhibitors (Fig. 4c).
We then generated Jurkat cells knocked down for the high-
affinity LTB4 receptor BLT-1 (Fig. 4d). We verified that blt-1 KD
did not affect the overall migration capacity of the cells, as
attested by the efficient migration towards stromal cell-derived
factor 1 (SDF-1) (Fig. 4e). In contrast, blt-1 KD Jurkat cells were
deficient for chemotaxis to C91/PL supernatant (Fig. 4f).
These results emphasize the capacity of HTLV-1-infected cells
to recruit potential target cells through LTB4 secretion.
LTB4 favours conjugate formation and viral spread in vitro.
To further evaluate the importance of LTB4 on HTLV-1
propagation, we determined the impact of blocking the LTB4
pathway on cell–cell contact formation and viral spread.
C91/PL cells were incubated with Jurkat cells for 30 min. Under
the selected conditions (20,000 cells ml 1 per cell line), around
50% of the C91/PL cells were in contact with Jurkat cells, as
quantified by double-blind counting on fluorescent microscope
(Fig. 5a). On pretreatment of C91/PL cells with LTB4 synthesis
inhibitors (MK886 or MAFP), the percentage of C91/PL cells
contacting Jurkat cells was significantly reduced (Fig. 5a).
Similarly, C91/PL cells formed fewer contacts with blt-1 KD
Jurkat cells, than with control shRNA-expressing Jurkat cells
(Fig. 5b). Together these data indicate that LTB4 secretion by
HTLV-1-infected cells favours the formation of cell–cell contacts.
We then cocultured C91/PL cells with Jurkat cells for 1 h, and
monitored viral transfer by determining the percentage of Gag
p24-positive Jurkat cells by flow cytometry. We found that
inhibition of LTB4 production significantly reduced viral transfer
to Jurkat cells (Fig. 5c). Likewise, viral transfer was significantly














































Figure 3 | Tax-induced pla2g4c expression depends on both NF-jB and CREB pathways. (a) Tax mutants fail to activate pla2g4c promoter. Pla2g4c
promoter was cloned into a luciferase reporter plasmid. 293T cells were transfected with the reporter plasmid (or the empty vector) and plasmids encoding
Tax wild type (WT) or the mutants M22 (that do not activate the NF-kB pathway) or M47 (that do not activate the CREB pathway). Protein expression
levels were detected by western blot 24 h post transfection (right panel). Luciferase activity (relative light units, RLU) was normalized to the protein
concentration. P value¼0.001; n¼4; mean±s.e.m.; Two-way ANOVA, Sydak’s post hoc test. (b) The CRE and kB sites are both required for Tax-induced
pla2g4c transactivation. 293T cells were transfected with a plasmid encoding Tax and with reporter plasmids with the luciferase gene downstream the
WT pla2g4c promoter, or promoters depleted for the CRE or the kB sites (generated by site-directed mutagenesis). P value o104; n¼4; mean±s.e.m.;
Two-way ANOVA, Sydak’s post hoc test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15890
4 NATURE COMMUNICATIONS | 8:15890 | DOI: 10.1038/ncomms15890 | www.nature.com/naturecommunications
sh-control Jurkat cells (Fig. 5d). In conclusion, LTB4 secretion by
HTLV-1-infected lymphocytes participates in viral spread
in vitro.
Treatment with MK886 reduces HTLV-1 PVL in vivo. We
have demonstrated that LTB4 secretion by cells chronically
infected with HTLV-1 increases T-cell recruitment, cellular
contact formation and viral transfer in vitro. This prompted us to
investigate whether blocking leukotrienes could prevent HTLV-1
propagation in vivo, in a humanized mouse model.
We generated humanized mice by inoculating immunodefi-
cient mice with human CD34þ haematopoietic progenitor cells.
Eight to ten weeks later, at a time when the human
hematolymphoid system is well established, mice were treated
with MK886 (or treated with DMSO as a control) and then
infected with HTLV-1 by intraperitoneal (IP) inoculation of
irradiated HTLV-1-infected MT2 cells (Fig. 6a). Mice were
injected IP with either MK886 or DMSO thrice a week for 6
weeks after infection. Then mice were killed.
Consistent with a previous report in humans20, we found that
LTB4 plasma levels were higher in HTLV-1-infected mice than in
uninfected animals (Fig. 6b). Treatment with MK886 resulted in
reduced LTB4 plasma concentrations (Fig. 6b).
We next determined the percentage of CD25þ CD4 T cells
among hCD45þ splenocytes. Indeed, this percentage is a
read out for high PVL in the mouse model39. As expected,
HTLV-1-infected mice injected with DMSO showed an increase
in the percentage of CD25þ human CD4 T cells compared to
uninfected animals (treated either with MK886 or DMSO)
(Fig. 6c). In contrast, the infected mice that were treated with
MK886 showed a more modest increase, suggesting that the
treatment may have affected HTLV-1 PVL. Consistent with these
observations, we found that PVLs of MK886-treated mice were
significantly reduced compared to those measured in DMSO-
injected mice (Fig. 6d).
This decrease in PVL may either point to impaired clonal
proliferation or a decrease in the number of HTLV-1-infected cell
clones. To discriminate between these two hypotheses, we used
an improved high-throughput sequencing (HTS) method to
simultaneously map proviral integration sites and measure the
abundance of the corresponding clones40.
The number of unique integration sites (UIS, corresponding to
the number of independent HTLV-1-infected cellular clones)
retrieved from MK886-treated mice was significantly lower than
that from DMSO-injected animals, despite equivalent sequencing
depths for both groups (Fig. 6e and Supplementary Table 1).
Interestingly, increasing the sequencing depth for MK886-treated
mouse samples did not alter the outcome regarding the number
of retrieved UIS, suggesting that the system reached saturation.
We examined the patterns of clonal distribution and found that
the relative abundance of HTLV-1-infected clones was not
significantly different between MK886-treated and
DMSO-injected mice (Supplementary Fig. 1). We next applied
a more appropriate approach to compare clone abundance
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Figure 4 | LTB4 secretion by HTLV-1-infected cells promote lymphocyte chemotaxis. (a) Drugs targeting the LTB4 synthesis pathway are efficient on
C91/PL cells. C91/PL cells were pretreated with 200 nM MK886 or 1 mM MAFP (or left untreated, UT) for 30 min. Spontaneous secretion was determined
by ELISA. P value o104; n¼4; mean±s.e.m.; ANOVA, Tukey’s post hoc test. (b) The supernatant of C91/PL cells treated with either MK886 or MAFP
fails at attracting Jurkat cells. The supernatant of pretreated C91/PL cells was added to the lower compartment of a Transwell device (5mm of porosity).
Jurkat cells (5 105 cells cm 1) were added to the upper compartment. The number of cells that had migrated to the lower compartment was determined
1 h later. The number of cells migrating was normalized to the number of cells that had migrated towards the supernatant of Jurkat cells. P value¼0.015;
n¼4; mean±s.e.m.; Friedman test, Dunn’s post hoc test. (c) Migration of CD4 T cells to C91/PL supernatant is reduced on either MK886 or MAFP
treatments. The migration of primary CD4 T cells (106 per cm) to culture supernatants in a Transwell device (3 mm of porosity) was determined as
previously. P value¼0.04; mean±s.e.m.; Friedman test, Dunn’s post hoc test. (d) BLT-1 expression was downregulated by transduction with lentivectors
encoding shRNAs. BLT-1 expression on Jurkat cells transduced with shRNAs targeting blt-1 (sh1 and sh2 in red and violet, respectively) or a control shRNA
(in grey) was detected by flow cytometry. (e) Blt-1 KD Jurkat cells migrate efficiently to SDF-1. The migration of the different Jurkat to SDF-1 (10 ng ml 1)
was determined on a Transwell device. The number of cells that had migrated in 1 h to the lower compartment was then determined. Mean±s.e.m.; n¼4.
(f) Chemotaxis of Jurkat cells to C91/PL supernatant is reduced on blt-1 KD. The different Jurkat cells were cultured in the upper compartment of a
Transwell device, and C91/PL supernatant was added to the lower compartment. The number of cells that had migrated in 1 h to the lower compartment
was then determined. P value¼0.02; n¼4; mean±s.e.m.; Friedman test, Dunn’s post hoc test.
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by comparing the abundance of HTLV-1-infected clones between
MK886-treated and DMSO-injected mice by iterative
subsampling, to correct for differences in the number of
sequencing reads that support LTR-host junctions between
samples, and thus for PVL. The proportion of abundant clones,
defined by proviral integration sites supported by Z2 reads, was
equivalent between groups (Fig. 6f and Supplementary Table 2),
strongly suggesting that MK886 treatment did not affect the
potential of the HTLV-1-infected cells to expand. Consistent with
this conclusion, using different thresholds (nZ3 and nZ4 reads
per UIS) resulted in similar observations (Supplementary
Table 2).
Altogether, our results demonstrate that MK886 treatment of
HTLV-1-infected animals has an impact on the number of
independent infected clones rather than on clonal expansion and
cell proliferation. Our work underscores the critical involvement
of leukotrienes in viral transmission and early phases of the
HTLV-1 life cycle.
Discussion
Unlike HIV-1, HTLV-1 infection occurs almost exclusively
through cell–cell contact41. Infection purportedly occurs
through viral synapse, transfer of viral biofilm or the formation
of conduits15. While the mechanisms of viral transfer have been
extensively described, little is known about the factors favouring
target cell recruitment and contact formation. Here we show that
HTLV-1-infected T cells are a source of LTB4, a potent
chemoattractant, which participates in the recruitment of target
cells and viral transmission, both in vitro and in vivo.
Trindade et al.20 have previously demonstrated that LTB4
levels are higher in the plasma of infected individuals than in the
plasma of non-infected individuals. High plasma levels of LTB4
could be attributed to high secretion by neutrophils, which are
potent LTB4 secretors and have an activated phenotype in
HTLV-1-infected individuals42. In addition, Trindade et al.20
showed that PBMCs from infected individuals secrete larger
amounts of LTB4 than control PBMCs, on ionomycin
stimulation. They suggested that LTB4 is released by monocytes
in response to viral sensing, since culture of PBMCs in the
presence of viral particles was sufficient to induce LTB4 secretion,
even in the absence of viral infection20. However, they have not
considered the possibility of LTB4 secretion by lymphocytes, as
normal T cells lack significant PLA2 activity and are incompetent
for AA and LTB4 synthesis35. Strikingly, we demonstrate that
primary HTLV-1-infected CD4 T cells spontaneously secrete
LTB4 as the consequence of Tax-induced cPLA2g expression.
The increase in pla2g4c transcription on HTLV-1 infection was
previously suggested by microarray and RNAseq studies43,44.
Tax-induced pla2g4c transcription depends on both CREB and
NF-kB activations. These two cellular pathways are also required
in TNFa-induced pla2g4c induction in bronchoepithelial cells38.
The LTB4 level released by infected cells is sufficient to recruit
lymphocytes (both from cell lines and primary CD4 T cells)
in vitro. Although it seems to be a major factor, LTB4 may not be
the only factor recruiting potential target cells. For example,
HTLV-1-infected lymphocytes selectively recruit CCR4þ CD4 T
cells in vitro via CCL22 secretion45. Authors suggested that
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Figure 5 | LTB4 secretion favours HTLV-1 viral transmission in vitro. (a) Blocking LTB4 production by C91/PL cells reduces the formation of cellular
contacts with Jurkat cells. C91/PL cells were pretreated (or not) with either MK886 or MAFP. C91/PL and Jurkat cells were stained with different cell
trackers to distinguish them. C91/PL and Jurkat cells were cocultured (ratio 1:1) for 30 min. The number of cell–cell contacts, or conjugates formed was then
counted. P value¼0.01; n¼4; mean±s.e.m.; Friedman test, Dunn’s post hoc test. (b) Blt-1 KD Jurkat cells form fewer contacts with C91/PL cells. C91/PL
cells were cultured with blt-1 KD Jurkat cells (sh1 or sh2), or Jurkat cells transduced with a control shRNA. The number of conjugates was then determined
after 30 min. Data were normalized to the number of conjugates formed with Jurkat cells. P value¼0.03; n¼ 3; mean±s.e.m.; Friedman test, Dunn’s post
hoc test. (c) Blocking LTB4 secretion by C91/PL reduces HTLV-1 viral transfer to Jurkat cells. C91/PL were treated or not with MK886 or MAFP, washed,
stained with cell tracker and cultured for 1 h with Jurkat cells. The percentage of P24-gag-positive Jurkat cells was then determined by flow cytometry.
P value¼0.02; n¼4; mean±s.e.m.; Friedman test, Dunn’s post hoc test. (d) Blt-1 downregulation on Jurkat cells reduces HTLV-1 spread. C91/PL cells were
stained with cell tracker, and cultured with blt-1 KD Jurkat cells (sh1 or sh2), or Jurkat cells transduced with a control shRNA for 1 h. The percentage of
P24-gag-positive Jurkat cells was then determined by flow cytometry. P value¼0.04; n¼4; mean±s.e.m.; Friedman test, Dunn’s post hoc test.
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cells express CCR4. However, a recent study demonstrated that
CCR4 expression can be induced on infection and HBZ
expression, hence it may not be initially expressed on target
cells46. In contrast, BLT-1, the high-affinity LTB4 receptor, is
expressed in a variety of inflammatory and immune cells,
including macrophages, activated CD4 T cells, effector CD8 T
cells and dendritic cells27. Thus, LTB4 could be involved in the
recruitment of a larger set of target cells.
To examine the relevance of LTB4 for viral propagation in vivo,
we employed a humanized mouse model of HTLV-1 infection47.
We speculated that HTLV-1 propagation may be affected on
inhibition of LTB4 production. We used MK886, a potent 5-LO
inhibitor, which has been extensively used to block leukotriene
secretion in vivo. We observed that MK886-treated mice
displayed decreased PVL when compared to DMSO-treated
HTLV-1-infected animals.
We verified by HTS mapping of HTLV-1 integration sites that
this decrease was not dependent on altered proliferation of
infected cells but rather on interference with virus propagation,
consistent with the significant reduction in the number of
independent clones observed on MK886-dependent inhibition of
LTB4. Given the low PVLs observed in MK886-treated animals,
we applied an improved HTS method, which includes several
critical modifications in library preparation, and increases the
sensitivity of the assay40.
While the oligoclonality index (OCI) introduced by
Gillet et al.48 has been frequently used as a measure of clone
abundance, OCI reflects the inequality of abundance between all
clones of a given sample rather than their absolute abundance. In
addition, OCI is highly dependent on sample size (in this case, the
number of reads that support LTR-host junctions), with a
























































































































Figure 6 | Blocking LTB4 synthesis during neoinfection in vivo results in lower HTLV-1 PVLs and a decrease in the number of infected clones.
(a) Experimental procedure. Mice were considered humanized 8–10 weeks after CD34þ cell transplantation. Mice were then treated with IP injection of
MK886 (5 nmol per mouse) three times a week. Injection with DMSO was used as control. One week after the initial injection, lethally irradiated MT2
cells were injected intraperitoneally. Six weeks after infection, mice were killed. Together, 14 mice were used. (b) LTB4 is increased in the plasma of
HTLV-1-infected humanized mice. Six weeks after infection, plasma was collected and LTB4 levels were determined by ELISA. P value¼0.006; bar
represents mean. Kruskal–Wallis test. (c) The frequency of human splenocytes expressing CD25 is lower in infected animals treated with MK886.
Six weeks after infection, mice were killed and splenocytes were collected. The percentage of human CD4 T cells (that is, hCD45þ ) positive for CD25 was
determined by flow cytometry. P value¼0.018; bar represents mean. Kruskal–Wallis test. (d) The PVL is lower in HTLV-1-infected mice treated with 5 nmol
MK886. PVL is reported as the number of genomic tax copies per 100 human cells on splenocytes. P value¼0.029; bar represents mean. Mann–Whitney
U-test. (e) The number of UIS is lower in HTLV-1-infected mice treated with MK886. The number of independent HTLV-1-infected clones was determined
by HTS clonality analysis (Supplementary Table 1). P value¼0.028; bar represents mean. Mann–Whitney U-test. (f) The abundance of infected clones is
not altered upon MK886 treatment. Abundant and non-abundant clones, defined by Z2 or a single sequencing read, respectively, were determined for
each animal by iterative subsampling (N¼ 1,000) of an equivalent number of reads (n¼ 59, Supplementary Table 1) within the total read number that
supported LTR-host junctions. Dot plots represent the distribution of the percentage of abundant clones (number of abundant clones/total number of UIS)
over 1,000 subsampling iterations for each animal. P value¼0.48; Median, quartile and 10–90th percentile are presented in the Box-and-Whisker plot.
Mann–Whitney U-test.
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correct for the significant differences in PVLs observed between
animals (low numbers of reads that support LTR-host junctions
in MK886-treated mice), a subsampling method was applied to
accurately compare clone abundances between groups. Using
different thresholds for defining clone abundance, we showed that
clone expansion in vivo is not affected by the perturbation of
LTB4 secretion.
We have demonstrated that MK886 treatment affects HTLV-1
propagation during neoinfection. It is unclear whether blocking
LTB4 has an impact on chronic infection: it has long been
considered that HTLV-1 propagates in an individual mostly by
clonal division of infected cells50. Thus, inhibiting LTB4 and viral
propagation may have little impact. However, this dogma has
been challenged by studies demonstrating the presence of
markers of recent infection (two LTR episomal virus) both in
primary infection and during persistent infection51–53. Moreover,
the number of infected clones present in PBMCs isolated from
HAM/TSP patients is significantly higher than in asymptomatic
carriers48, suggesting that infection cycles during chronic
infection may participate in HAM/TSP pathogenesis. Therefore,
we postulate that targeting de novo infection may prevent PVL
increase in asymptomatic carriers and HAM/TSP onset.
If the LTB4 pathway were to be considered as a therapeutic
target, one should envision the inhibition of the upstream enzyme
cPLA2g. Indeed, with such an inhibitor, cPLA2a-dependent
secretion, which is important in physiological and immune
responses54–56, would remain unaffected. Moreover, cPLA2g
inhibition would also result in the reduction of other AA
metabolites released by HTLV-1-infected cells, such as
prostaglandins E2, which are involved in LTR activation and
HTLV-1 viral expression57,58. Blocking cPLA2g could reduce
viral transmission both by preventing LTB4-mediated
recruitment of the target cell, and reducing prostaglandins
E2-mediated HTLV-1 replication.
In conclusion, this study demonstrates the critical role of LTB4
secretion in HTLV-1 transmission both in vitro and in vivo.
Methods
Cells. HTLV-1-chronically infected C91/PL and MT2 lymphocytes (Centre from
AIDS reagents, NIBSC) and control Jurkat T cells (TIB-152, ATCC) were grown in
RPMI (Gibco, Life Technologies) supplemented with 10% foetal bovine serum
and 1% penicillin/streptomycin. HEK293T cells were grown in DMEM (Gibco)
supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin.
We obtained PBMCs from HDs, HTLV-1 asymptomatic donors and HAM/TSP
patients in the context of a Biomedical Research Program approved by the
Committee for the Protection of Persons, Ile-de-France II, Paris (2012-10-04 SC).
All individuals gave informed consent. CD4 T cells were isolated from PBMCs by
negative selection using magnetic beads (Miltenyi Biotech).
LTB4 measurement and inhibitors. Cells were suspended at 106 cells ml 1 in
PBS and incubated for 30 min on ice. Cells were spun down at 400g for 5 min,
resuspended (107 cells ml 1) in RPMI (without serum) and incubated at 37 C for
30 min. LTB4 secretion was stopped by addition of cold PBS, cells were centrifuged
and supernatants were collected. LTB4 was then measured using an ELISA kit
(Cayman Chemical).
When mentioned, cells were pretreated for 30 min with 200 nM MK886 (a
FLAP irreversible inhibitor, Cayman Chemical), 1 mM MAFP (an inhibitor for both
group 4 and 6 PLA2s, Cayman Chemical) or 5 mM BEL (an inhibitor for PLA2G6s,
Cayman Chemical). Of note, these drugs are irreversible and washed away before
testing.
PVL quantification. CD4 T cells were isolated by positive selection and DNA
extracted using the QIAamp DNA blood mini kit (Qiagen). HTLV-1 PVL was
quantified through amplification and quantification of tax and albumin genes by
TaqMan real-time PCR, as described previously59.
The primer set used to amplify HTLV-1 tax gene was F: 50-CAAACCGTCA
AGCACAGCTT-30 and R: 50-TCTCCAAACACGTAGACTGGGT-30 ; the tax
probe was 50 6-FAM-TTCCCAGGGTTTGGACAGAGTCTTCT-TAMRA-30. The
primer set for albumin was F: 50-GCTGTCATCTCTTGTGGGCTGT-30 and R:
50-ACTCATGGGAGCTGCTGGTTC-30 and the probe 50-FAM-CCTGTCATGC
CCACACAAATCTCTCC-TAMRA-30 . Runs were performed in a 20ml volume
containing 500 ng of total DNA extract, primers and probe (a 200 nM
concentration of each), 1 Maxima Probe/ROX qPCR Master Mix
(Thermofisher). Thermocycling conditions were 2 min at 50 C and 10 min at
95 C, followed by 50 cycles at 95 C for 15 s and 60 C for 1 min. Quantification
was standardized using DNA extracted from the HTLV-1-positive cell line MT4 (7
proviral copies per cell).
Lentiviral vector production and transduction. Lentiviral vectors encoding
GFP alone or together with Tax or His-HBZ were described previously60. Vectors
were generated by transfection of HEK293T with psPAX-2 (encoding HIV Gag/
Pol, 4.68 mg, Addgene), pMD2.G (VSV-G, 2.52 mg, Addgene) and pSD101-Tax/
HBZ-IRES-GFP (9mg) plasmids. Lentivectors encoding shRNAs were generated by
transfection of HEK293T cells with psPAX-2, pMD2.G and pGIPZ plasmids
encoding anti-pla2g4c shRNAs (V3LHS_368941), anti-blt-1 shRNAs
(V2LHS_112397 and V3LHS_336099 for sh1 and sh2, respectively) or
non-targeting shRNA (CTRL sh) (GE Dharmacon). After 72 h, supernatants
were collected, centrifuged, filtered at 0.45 mm and stored at  80 C.
For protein encoding vectors, Jurkat cells were analysed 48 h post tranduction.
Protein expression was determined by western blot (anti-Tax (1/1,000, Tab172,
NIH), anti-GFP (1/8,000, clone JL-8, Clontech), anti-b-tubulin (1/2,000, D-10
polyclonal, Santa Cruz) and anti-His tag (1/1,000, clone H8, Abcam)). Uncropped
scans of western blots are shown in Supplementary Fig. 2. For shRNAs, cells were
selected for 10 days with puromycin (1 mg ml 1). KD efficiency was determined by
RT–qPCR for pla2g4c, or by flow cytometry for BLT-1 (primary antibody:
30 mg ml 1, clone 202/7B1, Bio-Rad).
Reverse transcription and quantitative PCR. Total cellular RNA was extracted
using the RNeasy Plus Mini Kit (Quiagen). cDNA was synthesized from 500 ng of
RNA using the superscript II reverse transcriptase (Invitrogen). mRNA levels of the
different pla2g4 genes were quantified by SYBR green-based qPCR using an
Eppendorf realplex2 thermal cycler (15 min at 95 C, 40 (15 s at 95 C, 20 s at
60 C, 30 s at 72 C)). GAPDH was used as a housekeeping gene. Primers were
described previously61.
Luciferase reporter assay. Pla2g4c promoter was amplified by PCR as
previously described38, and cloned into a pGL2 basic luciferase vector (Promega).
Site-directed mutagenesis was performed using the QuikChange II XL
Site-Directed Mutagenesis kit (Agilent Technologies) and the primers previously
used38.
HEK293T cells (6 105) were transfected with pGL2-pla2g4c promoter
plasmids and empty pSG5M or pSG5M-Tax (WT or mutants) plasmids using
LipoD293 (SignaGen) following the manufacturer’s instructions. Luciferase activity
was measured 24 h after transfection with the luciferase assay system (Promega)
and chemiluminescence was detected using an EnSpire Multimode Plate Reader
(PerkinElmer). The protein concentration was determined using the DC Protein
Assay (Bio-Rad) to normalize for luciferase activity.
Transwell assay. Jurkat migration to SDF-1 (10 ng ml 1, Sigma-Aldrich) or cell
culture supernatant through a 5 mm-porosity Transwell filter (Corning) was
determined by adding 2 105 lymphocytes to the upper compartment and
counting the cells present in the lower compartment after 1 h.
For the migration assay with primary cells, CD4 T cells were isolated from
PBMCs by positive selection using magnetic beads (Miltenyi Biotech), cultured
with IL-2 and activated with PHA for 24 h, and 5 105 T cells were added onto a
3 mm-porosity Transwell device.
Conjugate formation. HTLV-1-infected cells (C91/PL cells treated or not with the
different drugs) and target cells (Jurkat cells transduced or not with shRNA
encoding lentiviral vectors) were stained with distinct fluorescent dyes (CellTracker
Red CMPTX or CellTracker Green CMFDA, 0.5 mM, Molecular Probes), and
cocultured (ratio 1:1, that is, 20,000 of each cell type per ml) on 0.01% poly-L-lysine
(Sigma-Aldrich) coated glass coverslips for 30 min at 37 C. Cells were then fixed
(2% paraformaldehyde) and mounted in DAPI Fluormount G (Southern Biotech).
The percentage of C91/PL cells in contact with potential target cells was then
determined by double-blind counting, by two distinct operators. For each replicate,
at least 10 different fields were observed for each condition, corresponding to at
least 300 counted HTLV-1-infected cells per condition.
Analysis of cell-to-cell HTLV-1 transfer. HTLV-1-infected cells (C91/PL cells
treated or not with the different drugs) were stained with a fluorescent dye
(CellTracker Green CMFDA) and cultured (ratio 1:1, that is, 20,000 of each cell
type per ml) with target cells (Jurkat cells transduced or not with shRNA encoding
lentiviral vectors) for 1 h. Cells were then fixed with 2% paraformaldehyde,
permeabilized with triton 0.05% and stained for intracellular p24 expression
(Zeptometrix Corporation). Analysis was performed with a FACSCalibur flow
cytometer (BD Biosciences).
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Isolation of human CD34þ cells from cord blood samples. Umbilical cord
bloods were obtained from healthy full-term newborns with written parental
informed consent according to the guidelines of the medical and ethical
committees of Hospices Civils de Lyon and of Agence de la biomédecine, Paris,
France.
After density gradient centrifugation of human cord blood, CD34þ cells were
enriched twice using immunomagnetic beads according to the manufacturer’s
instructions (CD34þ MicroBead Kit, Miltenyi Biotec). Purity (Z95%) was
evaluated by FACS analysis using human PE-CD34 antibody (1/50, ref. 130-081-
002, Miltenyi Biotec). Cells were frozen before the transplantation when newborn
mice were available.
Infection of humanized mice and sample analyses. NOD.Cg-Prkdcscid
Il2rgtm1Wjl Tg(HLA.A2.1)1Enge/SzJ (NSG-HLA-A2/HDD) mice
(Jackson Laboratory; males and females of 2–5 days of age) were bred and
maintained under pathogen-free conditions. Newborn mice were sublethally
irradiated with 1.1 Gray (320 kV, 25 mA; XRad-320, PXI Precision XRay) and
injected intrahepatically with 2 105 human CD34þ haematopoietic stem cells
isolated from cord blood samples. After 8–10 weeks, humanized mice (Z30%
CD45þ cells in peripheral blood) were first treated with MK886 (IP injection of
5 nmol per mouse) (or with the vehicle, DMSO) thrice a week. This treatment was
maintained till the mouse was killed. One week after the initial MK886 injection,
lethally irradiated MT2 cells (105 cells per mouse) were intraperitoneally injected as
previously described39. Mock-infected mice were injected with PBS.
Six weeks after infection, mice were killed. Blood was drawn on ACD and
plasma collected on centrifugation and processed for ELISA. Spleens were collected
and gently minced in PBS to obtain a single-cell suspension. Monoclonal
antibodies provided by BD Biosciences were used for cell staining in a 1% BSA
0.1% sodium azide PBS buffer: Pacific Blue-hCD45 (1/250, ref. 560367), FITC-CD3
(1/50, ref. 555339), PE-hCD8 (1/50, ref. 555367), PE-Cy7-hCD4 (1/50, ref.
557852), APC-hCD25 (1/20, ref. 555434). Cells were incubated for 30 min in the
dark at 4 C with previously determined concentration of the relevant antibodies.
Cells were gated to exclude doublets. Compensations were realized using Miltenyi
MACS Comp Beads. Fluorescence was acquired using FACSCanto II and BDSDiva
software (Becton Dickinson Immunocytometry Systems) and analysed using
FlowJo software (Treestar). PVL was expressed as the number of copies of tax per
100 human cells as previously described39.
Animal experimentation was performed in strict accordance with the French
‘Comité National de Réflexion Ethique sur l’Expérimentation Animale, no. 15’ and
the ethical guidelines for the care of these mice of the Plateau de Biologie
Expérimentale de la Souris (PBES, UMS 3444) at École Normale Supérieure de
Lyon. All efforts were made to minimize animal suffering.
HTS clonality analysis. To determine the number and abundance of HTLV-1-
infected clones in humanized mice, we used an improved quantitative HTS method
to map the proviral integration sites in the human genome and simultaneously
measure the abundance of the corresponding clones40. The method includes
several critical modifications in library preparation and data analysis, overcoming
some of the limitations of previously published protocols48. The dynamic range of
the technique was increased by assaying both the 50LTR and 30LTR, allowing better
determination of clone abundance. An extension step with Biotin-11-dUTP
simultaneously end-repairs and facilitates streptavidin-based enrichment of
LTR-positive fragments, increasing the sensitivity of the assay, followed by limited
PCR to avoid PCR duplicates. Off-the-shelf Illumina primers replaced custom
sequencing primers for the addition of adaptors and indexes, simplifying library
multiplexing and reducing both the cost and hands-on time. Libraries were
prepared starting from 500 ng DNA and sequenced on an Illumina MiSeq
instrument. Hundred and fifty base pairs paired-end reads were acquired and
sequencing reads that supported either the 50 or the 30LTR-host junctions were
retained (Supplementary Table 1). The number of UIS and their abundance were
determined.
To compare the abundance of the HTLV-1-infected clones between individuals
and between groups, it was necessary to correct for differences in the number of
sequencing reads that support LTR-host junctions between samples, and thus
adjust for PVL. This was achieved by iterative (N¼ 1,000) subsampling of an
equivalent number of reads within the full data set of LTR-host reads obtained for
each animal, the sampling size being determined by the animal with the lowest read
number across all samples (n¼ 59, filtered reads reported in Supplementary
Table 1). For each animal, this yielded a number of UIS, a number of
non-abundant clones (defined by the number of UIS supported by a single
sequencing read) and a number of abundant clones (defined by the number of UIS
supported by Z2 reads) for each of the 1,000 subsampling iterations. Additional
thresholds for defining clone abundance were also used (Z3 reads per UIS and Z4
reads per UIS). Of note, for the sample with the lowest read number (59), each
iteration consisted in the sampling of all reads. This generated N¼ 1,000 times an
identical value, symbolized by a single data point (Fig. 6f). Percentage abundant
clones¼ number of abundant clones/total number of UIS.
Statistical analyses. Analyses were performed using Prism software (v.6,
Graphpad). Results were considered to be significant when Po0.05.
Data availability. All relevant data are available from the authors on request.
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